vs
Emerald Holding, Inc.（EEX）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Emerald Holding, Inc.的1.7倍（$219.9M vs $132.7M），Orthofix Medical Inc.净利率更高（-1.0% vs -22.8%，领先21.7%），Emerald Holding, Inc.同比增速更快（24.3% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $11.7M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -0.3%）
TVS Emerald Haven地产有限公司是一家印度房地产开发企业，总部位于泰米尔纳德邦金奈，为TVS控股旗下子公司，专注于打造可持续居住社区以及各类城市开发项目，在印度本土房地产业务领域拥有清晰的业务定位。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
EEX vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.7倍
$132.7M
营收增速更快
EEX
高出22.3%
2.0%
净利率更高
OFIX
高出21.7%
-22.8%
自由现金流更多
OFIX
多$5.1M
$11.7M
两年增速更快
OFIX
近两年复合增速
-0.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $132.7M | $219.9M |
| 净利润 | $-30.2M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | -11.8% | 0.2% |
| 净利率 | -22.8% | -1.0% |
| 营收同比 | 24.3% | 2.0% |
| 净利润同比 | -692.2% | 92.4% |
| 每股收益（稀释后） | $-0.15 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EEXOFIX
| Q4 25 | $132.7M | $219.9M | ||
| Q3 25 | $77.5M | $205.6M | ||
| Q2 25 | $105.5M | $203.1M | ||
| Q1 25 | $147.7M | $193.6M | ||
| Q4 24 | $106.8M | $215.7M | ||
| Q3 24 | $72.6M | $196.6M | ||
| Q2 24 | $86.0M | $198.6M | ||
| Q1 24 | $133.4M | $188.6M |
净利润EEXOFIX
| Q4 25 | $-30.2M | $-2.2M | ||
| Q3 25 | $-14.4M | $-22.8M | ||
| Q2 25 | $-1.4M | $-14.1M | ||
| Q1 25 | $15.3M | $-53.1M | ||
| Q4 24 | $5.1M | $-29.1M | ||
| Q3 24 | $-11.1M | $-27.4M | ||
| Q2 24 | $-2.8M | $-33.4M | ||
| Q1 24 | $11.0M | $-36.0M |
毛利率EEXOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率EEXOFIX
| Q4 25 | -11.8% | 0.2% | ||
| Q3 25 | -10.1% | -8.3% | ||
| Q2 25 | 9.7% | -7.9% | ||
| Q1 25 | 24.2% | -25.2% | ||
| Q4 24 | 19.5% | -5.3% | ||
| Q3 24 | -6.5% | -9.6% | ||
| Q2 24 | 7.4% | -12.5% | ||
| Q1 24 | 18.2% | -15.6% |
净利率EEXOFIX
| Q4 25 | -22.8% | -1.0% | ||
| Q3 25 | -18.6% | -11.1% | ||
| Q2 25 | -1.3% | -6.9% | ||
| Q1 25 | 10.4% | -27.4% | ||
| Q4 24 | 4.8% | -13.5% | ||
| Q3 24 | -15.3% | -13.9% | ||
| Q2 24 | -3.3% | -16.8% | ||
| Q1 24 | 8.2% | -19.1% |
每股收益（稀释后）EEXOFIX
| Q4 25 | $-0.15 | $-0.05 | ||
| Q3 25 | $-0.07 | $-0.57 | ||
| Q2 25 | $-0.01 | $-0.36 | ||
| Q1 25 | $0.08 | $-1.35 | ||
| Q4 24 | $0.01 | $-0.76 | ||
| Q3 24 | $-0.05 | $-0.71 | ||
| Q2 24 | $-0.03 | $-0.88 | ||
| Q1 24 | $0.00 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $100.9M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $338.8M | $450.0M |
| 总资产 | $1.2B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EEXOFIX
| Q4 25 | $100.9M | $82.0M | ||
| Q3 25 | $95.4M | $62.9M | ||
| Q2 25 | $156.4M | $65.6M | ||
| Q1 25 | $276.8M | $58.0M | ||
| Q4 24 | $194.8M | $83.2M | ||
| Q3 24 | $188.9M | $30.1M | ||
| Q2 24 | $193.2M | $26.4M | ||
| Q1 24 | $186.8M | $27.0M |
总债务EEXOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益EEXOFIX
| Q4 25 | $338.8M | $450.0M | ||
| Q3 25 | $369.5M | $442.5M | ||
| Q2 25 | $389.4M | $458.3M | ||
| Q1 25 | $392.1M | $458.3M | ||
| Q4 24 | $385.9M | $503.1M | ||
| Q3 24 | $391.1M | $525.9M | ||
| Q2 24 | $407.6M | $546.0M | ||
| Q1 24 | $-90.7M | $570.3M |
总资产EEXOFIX
| Q4 25 | $1.2B | $850.6M | ||
| Q3 25 | $1.2B | $832.6M | ||
| Q2 25 | $1.2B | $837.2M | ||
| Q1 25 | $1.2B | $823.1M | ||
| Q4 24 | $1.0B | $893.3M | ||
| Q3 24 | $1.1B | $867.9M | ||
| Q2 24 | $1.1B | $882.0M | ||
| Q1 24 | $1.1B | $906.0M |
负债/权益比EEXOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $12.3M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $11.7M | $16.8M |
| 自由现金流率自由现金流/营收 | 8.8% | 7.6% |
| 资本支出强度资本支出/营收 | 0.5% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $41.4M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流EEXOFIX
| Q4 25 | $12.3M | $27.7M | ||
| Q3 25 | $1.8M | $12.4M | ||
| Q2 25 | $15.9M | $11.6M | ||
| Q1 25 | $12.6M | $-18.4M | ||
| Q4 24 | $20.6M | $23.7M | ||
| Q3 24 | $9.1M | $11.7M | ||
| Q2 24 | $9.8M | $9.0M | ||
| Q1 24 | $7.3M | $-18.6M |
自由现金流EEXOFIX
| Q4 25 | $11.7M | $16.8M | ||
| Q3 25 | $1.5M | $2.5M | ||
| Q2 25 | $15.8M | $4.5M | ||
| Q1 25 | $12.4M | $-25.1M | ||
| Q4 24 | $19.9M | $15.2M | ||
| Q3 24 | $9.0M | $6.3M | ||
| Q2 24 | $9.6M | $-360.0K | ||
| Q1 24 | $7.0M | $-29.1M |
自由现金流率EEXOFIX
| Q4 25 | 8.8% | 7.6% | ||
| Q3 25 | 1.9% | 1.2% | ||
| Q2 25 | 15.0% | 2.2% | ||
| Q1 25 | 8.4% | -13.0% | ||
| Q4 24 | 18.6% | 7.0% | ||
| Q3 24 | 12.4% | 3.2% | ||
| Q2 24 | 11.2% | -0.2% | ||
| Q1 24 | 5.2% | -15.4% |
资本支出强度EEXOFIX
| Q4 25 | 0.5% | 4.9% | ||
| Q3 25 | 0.4% | 4.8% | ||
| Q2 25 | 0.1% | 3.5% | ||
| Q1 25 | 0.1% | 3.5% | ||
| Q4 24 | 0.7% | 4.0% | ||
| Q3 24 | 0.1% | 2.7% | ||
| Q2 24 | 0.2% | 4.7% | ||
| Q1 24 | 0.2% | 5.6% |
现金转化率EEXOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.82× | — | ||
| Q4 24 | 4.04× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.66× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EEX
| Connections Segment | $121.9M | 92% |
| Commerce Segment | $5.5M | 4% |
| Content | $5.3M | 4% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
